Assay

Menarini Silicon Biosystems Announces Study Results Presented at American Society of Hematology (ASH) Annual Meeting Highlighting CELLSEARCH® CMMC assay, a Non-Invasive Liquid Biopsy for the Quantification and Molecular Characterization of Circulating Mu

Retrieved on: 
Tuesday, December 14, 2021
CMMC, Disease management, Nxt, International Myeloma Foundation, Doctor of Philosophy, CNV, Assay, Disease, MSB, Solution, Multiple Myeloma Research Foundation, FDA, Research, ISO, Genomics, Education, NCI-designated Cancer Center, Adult, Hospital, Biomarker, Immunotherapy, MM, Blood, Inflore, MMRF, ASH, SMM, Dana–Farber Cancer Institute, Cancer, Bone marrow, CEO, Biotechnology, Tissue, Liquid biopsy, MGUS, Precision medicine, Silicon, Industry, Harvard Medical School, News, Patient, Medical imaging, Fine chemical, Pharmaceutical industry, Medicine, Multiple myeloma

The oral presentation took place at the ASH 2021 Annual Meeting in Atlanta on Saturday December 11th at 10:45am.

Key Points: 
  • The oral presentation took place at the ASH 2021 Annual Meeting in Atlanta on Saturday December 11th at 10:45am.
  • "As a patient focused organization, the MMRF is committed to advancing innovative research to improve clinical care and disease management.
  • These findings are an important step forward in liquid biopsy for advanced molecular diagnostics for clinicians and patients alike."
  • The CELLSEARCH Circulating Multiple Myeloma Cells (CMMC) assay is the first test of its kind to enumerate circulating multiple myeloma cells from peripheral blood.

Analysis Presented at SABCS 2021 Confirms MammaPrint® and BluePrint® Predict Outcomes Following Neoadjuvant Chemotherapy

Retrieved on: 
Thursday, December 9, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Physician, Risk, Research, Neoplasm, Patient, Luminal, NAC, Transcriptome, Chain reaction, Woman, Â, Oncology, EBC, Classification, Quality of life, Behavior, Breast cancer, High Risk, Cedars-Sinai Medical Center, Biomarker, Recurrence, MD, Department, Division, Surgeon, Assay, Blueprint, Association, Poster, Prognosis, Biology, Marie Cassidy, Surgical oncology, Medical imaging

Agendia, Inc. , a world leader in precision oncology for breast cancer, today shared data demonstrating the ability of MammaPrint and BluePrint to predict patient outcomes following neoadjuvant chemotherapy (NAC) at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021).

Key Points: 
  • Agendia, Inc. , a world leader in precision oncology for breast cancer, today shared data demonstrating the ability of MammaPrint and BluePrint to predict patient outcomes following neoadjuvant chemotherapy (NAC) at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021).
  • The poster, titled MammaPrint and BluePrint are prognostic of outcome following neoadjuvant chemotherapy, presents findings that indicate MammaPrint and BluePrint accurately correlated with chemosensitivity and outcomes in NAC-treated patients.
  • Notably, approximately 1 in 4 tumors which were MammaPrint High Risk (Luminal B) prior to NAC became MammaPrint Low Risk (Luminal A) when the post-treatment tissue was analyzed.
  • Patients with reclassified MammaPrint Low Risk tumors had improved five-year outcomes compared to patients that remained High Risk after treatment.

10x Genomics Recognized on The Scientist's Top 10 Innovations List for Fifth Consecutive Year

Retrieved on: 
Wednesday, December 1, 2021
Gene expression, Single cell, Microfluidics, Security (finance), Disclosure, Spatial analysis, Cell, Neuroscience, Technology, Time, Publication, Acquisition, Biology, Genomics, Health, ATAC, Chromium, Regulation, R&D, U.S. Securities and Exchange Commission, Chromatin, Nature, Spatial transcriptomics, Software, Research, Entrepreneurship, Assay, Infection, Patent, Culture, Social media, Efficiency, Immune system, B cell, Scientist, Regulation Fair Disclosure, Fine chemical, Vaccine

This recognition marks the fifth consecutive year that a 10x Genomics product made the list, with a total of seven products appearing as Top 10 Innovations since 2015.

Key Points: 
  • This recognition marks the fifth consecutive year that a 10x Genomics product made the list, with a total of seven products appearing as Top 10 Innovations since 2015.
  • "We're honored and humbled to be consistently recognized by The Scientist for our culture of innovation and strong cadence of technological advancement.
  • To see the full list of The Scientist's 2021 Top 10 Innovations, please visit www.the-scientist.com/features/2021-top-10-innovations-69438 .
  • 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health.

Worldwide Chromatography Reagents Industry to 2026 - Featuring Agilent Technologies, Avantor and Thermo Fisher Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, November 12, 2021
Biotechnology, Chemicals, Plastics, Health, Manufacturing, Population, Adoption, Medicine, USP, Chromatography, USD, Investment, GC, Research, IFPMA, HPLC, Maximal and minimal elements, Food, Drug discovery, Pharmacokinetics, Patient, Risk, Drug development, Ageing, Assay, Fine chemical

The pharmaceutical industry is one of the most regulated industries worldwide, since the drug products must be safe and effective.

Key Points: 
  • The pharmaceutical industry is one of the most regulated industries worldwide, since the drug products must be safe and effective.
  • The HPLC chromatography technique is the most important analytical techniques used in the pharmaceutical business for identifying and quantifying pharmaceuticals.
  • This chromatography technique is commonly utilized in pharmacokinetics, bioassays, and metabolic research, owing to its great sensitivity and selectivity.
  • The increased adoption of chromatography technique, majorly in food and beverage and pharmaceutical industries, drives the demand for chromatography reagents in the region.

Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib

Retrieved on: 
Thursday, November 11, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Hematology, Population, AML, First Round Capital, Cancer, Boehringer Ingelheim, ODD, Sarcoma, Engineering, RMS, Founders Fund, Acute myeloid leukemia, Food, Machine learning, Automation, Labs, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Software, HIV disease progression rates, Partnership, Builder, Y Combinator, Therapy, Rhabdomyosarcoma, Capital Group Companies, Adult, Patient, FDA, Drug development, Lymphoma, Assay, Orphan, Pharmaceutical industry, Volasertib, Notable, VOLASERTIB, NOTABLE

Notable Labs, Inc. (Notable), a pioneer and developer of predictive precision medicines, has obtained worldwide rights to volasertib from Oncoheroes Biosciences Inc., a Boston-based biotechnology company focused on advancing new therapies for childhood cancer.

Key Points: 
  • Notable Labs, Inc. (Notable), a pioneer and developer of predictive precision medicines, has obtained worldwide rights to volasertib from Oncoheroes Biosciences Inc., a Boston-based biotechnology company focused on advancing new therapies for childhood cancer.
  • Under terms of the agreement, Notable will have exclusive rights to develop and commercialize volasertib in leukemias, lymphomas and other adult cancer indications.
  • Oncoheroes will retain the license for development and commercialization of volasertib in pediatric indications.
  • Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines.

Enterome - Significant Progress with OncoMimics™ and EndoMimics™ pipelines of transformational medicines for cancer and immune diseases

Retrieved on: 
Thursday, November 4, 2021
Peptide, Assay, Cancer, Genome, IBD, Database, Patient, Drug discovery, Lymphoma, Brain, Glioblastoma, Adrenal tumor, Company, Clinical trial, Inflammatory bowel disease, Immune system, Wilms' tumor, Pharmaceutical industry

PARIS, Nov. 4, 2021 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its unique ability to decode the gut microbiome's interaction with the immune system, announces the launch of its new corporate brand and visual identity supported by a new website. 

Key Points: 
  • These changes reflect the significant progress that Enterome has made with its two advanced, fully owned, OncoMimics and EndoMimics pipelines of transformational medicines for cancer and immune diseases, respectively.
  • Enterome's most advanced OncoMimics drug candidates are:
    EO2401, a therapeutic cancer vaccine candidate currently in clinical development for recurrent glioblastoma and adrenal tumors.
  • This use of cutting-edge tools means that Enterome's platform is more efficient than well established, labor-intensive drug discovery approaches.
  • Enterome's platform has already demonstrated it is highly productive and has generated multiple pipelines of transformative drug candidates, targeting a broad range of therapeutic areas.

Enterome - Significant Progress with OncoMimics™ and EndoMimics™ pipelines of transformational medicines for cancer and immune diseases

Retrieved on: 
Thursday, November 4, 2021
Peptide, Assay, Cancer, Genome, IBD, Database, Patient, Drug discovery, Lymphoma, Brain, Glioblastoma, Adrenal tumor, Company, Clinical trial, Inflammatory bowel disease, Immune system, Wilms' tumor, Pharmaceutical industry

These changes reflect the significant progress that Enterome has made with its two advanced, fully owned, OncoMimics and EndoMimics pipelines of transformational medicines for cancer and immune diseases, respectively.

Key Points: 
  • These changes reflect the significant progress that Enterome has made with its two advanced, fully owned, OncoMimics and EndoMimics pipelines of transformational medicines for cancer and immune diseases, respectively.
  • Enterome's most advanced OncoMimics drug candidates are:
    EO2401, a therapeutic cancer vaccine candidate currently in clinical development for recurrent glioblastoma and adrenal tumors.
  • This use of cutting-edge tools means that Enterome's platform is more efficient than well established, labor-intensive drug discovery approaches.
  • Enterome's platform has already demonstrated it is highly productive and has generated multiple pipelines of transformative drug candidates, targeting a broad range of therapeutic areas.

KBI Biopharma Completes Eurofins DiscoverX Products Specialized Bioassay Certification Program

Retrieved on: 
Monday, October 11, 2021
Biotechnology, Pharmaceutical, Health, CGMP, GMP, MOA, LLC, Drug discovery, Biotechnology, Cros, Program, Eurofins Scientific, Drug development, KBI, Industry, Certification, Enzyme, QC, Triangle Park (Quezon City), CEO, Solution, Assay, Organization, Environment, Pharmaceutical industry, Vaccine, Fine chemical, Eurofins DiscoverX Products LLC, KBI Biopharma, Inc., EUROFINS DISCOVERX PRODUCTS LLC, KBI BIOPHARMA, INC.

Eurofins DiscoverX Products, LLC (Eurofins DiscoverX), an industry leader in assays for drug discovery, development, and QC lot release, announced today the expansion of its Bioassay Certification Program through its certification of KBI Biopharma, Inc. (KBI) , a JSR Life Sciences company.

Key Points: 
  • Eurofins DiscoverX Products, LLC (Eurofins DiscoverX), an industry leader in assays for drug discovery, development, and QC lot release, announced today the expansion of its Bioassay Certification Program through its certification of KBI Biopharma, Inc. (KBI) , a JSR Life Sciences company.
  • The advantage of expanding the Bioassay Certification Program, Eurofins DiscoverX leaders say, is that it offers a potent new tool in meeting the needs of biopharma clients seeking CROs and CDMOs that can run its bioassay potency assays when moving their drug product downstream through the development process.
  • KBI Biopharma earned the certification by demonstrating its proficiency in advancing programs for potency under GMP conditions, using the Eurofins DiscoverX PathHunter assay platform, including the successful transfer of multiple client-sponsored GMP validated programs.
  • Eurofins DiscoverX is the products brand of Eurofins Discovery, the industrys leading drug discovery products and services provider.

AMDL, a Subsidiary of China Biotech Services, is Exclusively Licensed to Distribute FDA Approved Lung & Colon Cancer Companion Diagnostic Assay in Several Asian Regions Including China

Retrieved on: 
Tuesday, August 10, 2021
Pillar, Technology, Patent, Cetuximab, Targeted therapy, IVD, Colorectal cancer, TKI, FDA, CRC, Food and Drug Administration, Massachusetts General Hospital, Panitumumab, Cancer, Pathology, SER, Assay, EGFR, PCR, La Gran Colombia University, Dana–Farber Cancer Institute, Partnership, PMA, KRAS, DNA, Yale University, NSCLC, B-cell lymphoma, CH, Science, Patient, Hospital Insurance and Diagnostic Services Act, Hong Kong Science and Technology Parks Corporation, Harvard University, Large-cell lung carcinoma, Coronavirus, NGS, Biotechnology, Lung, ASEAN, Leukemia, Company, News

Pillar, an invested enterprise of CH BIOTECH SER, received the Premarket Approval ("PMA") on its oncoReveal(TM) Dx Lung and Colon Cancer Assay from FDA on July 30th, 2021.

Key Points: 
  • Pillar, an invested enterprise of CH BIOTECH SER, received the Premarket Approval ("PMA") on its oncoReveal(TM) Dx Lung and Colon Cancer Assay from FDA on July 30th, 2021.
  • The Assay is a NGS tissue-based companion diagnostic test for qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
  • China Biotech Services Holdings Limited (CH BIOTECH SER) was included in the MSCI Hong Kong Micro Cap Index in May 2018.
  • This press release is issued by the Porda Havas International Financial Communications Group on behalf of China Biotech Services Holdings Limited.

OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program

Retrieved on: 
Tuesday, August 3, 2021
Transport in England, Laboratory techniques, Assay, Biochemistry, Titration, A30 road, Transport in the United Kingdom, A30, England

ROCKVILLE, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that its subsidiary Curetis GmbH and its instrument development and engineering partner have assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform. The assembly of the instruments marks the successful completion of a major development milestone in the Unyvero A30 program. The A30 RQ analyzers will now proceed into final verification and validation testing.

Key Points: 
  • The assembly of the instruments marks the successful completion of a major development milestone in the Unyvero A30 program.
  • Furthermore, the Unyvero A30 RQ platform can be made available to third party development and commercialization partners and licensees for their own assay menu and product portfolio.
  • The Unyvero A30 RQ platform is designed to allow straightforward migration of third party assays using well-established real time PCR technology.
  • This press release includes statements regarding the development of OpGens Unyvero A30 RQ platform.